Earnings History Data for Aeglea BioTherapeutics, Inc. (AGLE) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 02-03-2023 | PM | 7:00 AM ET (Mar 2) |
AGLE | Aeglea BioTherapeutics | 24.00 | -0.18 | -0.20 | 0.00 | Aeglea BioTherapeutics GAAP EPS of -$0.99 beats by $0.03, revenue of $2.33M beats by $0.1M [3/2/2023 8:33 AM] |
0.3923 | 0.0 (-0.71%) |
0.0 | 0.0 (0.00%) |
0.33 - 3.17 | 126,571 | 230,000 | 0 | |
| 05-05-2022 | PM | AGLE | Aeglea BioTherapeutics | 78.00 | -0.37 | -0.35 | 0.00 | Aeglea BioTherapeutics GAAP EPS of -$0.37, revenue of $1.36B [5/5/2022 8:05 AM] |
1.57 | 0.01 (0.64%) |
1.40 | -0.16 (-10.26%) |
1.40 - 8.50 | 635,683 | 250,000 | 29,963 | ||
|
||||||||||||||||||
| 08-03-2022 | PM | AGLE | Aeglea BioTherapeutics | 111.00 | -0.31 | -0.32 | 0.00 | Aeglea BioTherapeutics GAAP EPS of -$1.00 beats by $0.02, revenue of $18.73M beats by $1.33M [3/8/2022 7:23 AM] |
2.45 | 0.12 (5.15%) |
0.0 | 0.0 (0.00%) |
2.14 - 8.79 | 330,772 | 260,000 | 0 | ||
| 05-08-2021 | PM | AGLE | Aeglea Biotherapeutics, Inc. | 307.00 | -0.10 | -0.19 | 0.00 | Aeglea BioTherapeutics reports Q2 results [8/5/2021 9:13 AM] |
6.79 | 0.19 (2.88%) |
6.60 | 0.0 (0.00%) |
6.04 - 9.90 | 85,246 | 80,000 | 2,324 | ||
| 10-05-2021 | PM | AGLE | Aeglea Biotherapeutics, Inc. | 357.00 | -0.28 | -0.13 | 0.00 | Aeglea BioTherapeutics EPS misses by $0.14 [5/10/2021 8:47 AM] |
7.05 | -0.19 (-2.62%) |
7.24 | 0.0 (0.00%) |
6.20 - 11.38 | 131,700 | 130,000 | 929 | ||
| 18-03-2021 | PM | 8:30 AM ET (Mar 18) |
AGLE | Aeglea Biotherapeutics, Inc. | 367.00 | -0.34 | -0.29 | 0.00 | Aeglea BioTherapeutics EPS beats by $0.04 [3/18/2021 8:47 AM] |
7.54 | -0.22 (-2.84%) |
7.38 | -0.38 (-4.90%) |
3.61 - 11.38 | 115,819 | 250,000 | 2,002 | |
| 05-11-2020 | PM | 8:30 AM ET (Nov 5) |
AGLE | Aeglea BioTherapeutics, Inc. | 330.04 | -0.29 | -0.38 | -0.66 | Aeglea BioTherapeutics EPS beats by $0.11 [11/5/2020 8:38 AM] |
7.92 | 0.10 (1.28%) |
7.92 | 0.0 (0.00%) |
3.50 - 11.38 | 107,922 | 493,926 | 34,055 | |
|
|
||||||||||||||||||
| 10-08-2020 | PM | 8:30 AM ET (Aug 10) |
AGLE | Aeglea BioTherapeutics, Inc. | 311.31 | -0.40 | -0.39 | -0.55 | Aeglea BioTherapeutics EPS beats by $0.03 [8/10/2020 8:42 AM] |
6.75 | 0.24 (3.69%) |
6.51 | 0.0 (0.00%) |
3.50 - 11.38 | 119,841 | 226,466 | 2,542 | |
|
|
||||||||||||||||||